Pull to refresh
Logo
Daily Brief
Following Why Sign Up
CP

Chris Peetz

Co-founder and Chief Executive Officer, Mirum Pharmaceuticals

Appears in 1 story

Notable Quotes

We believe we are well positioned to potentially be the first and only medicine approved in this setting.

Stories

First potential therapy for primary sclerosing cholangitis clears Phase 2b

New Capabilities

Leading Mirum's push to file volixibat with the FDA in late 2026

For the roughly 30,000 Americans living with primary sclerosing cholangitis (PSC), the U.S. Food and Drug Administration has never approved a single drug. On May 4, 2026, that drought moved closer to ending: Mirum Pharmaceuticals reported that its experimental pill volixibat hit the primary endpoint of its Phase 2b VISTAS trial, cutting the relentless itch that defines the disease by a wide margin over placebo.

Updated 3 hours ago